Holen Sie sich die Stockscreener-App
19.68
4.51%
0.85
Schlusskurs vom Vortag:
$18.83
Offen:
$19
24-Stunden-Volumen:
2.80M
Relative Volume:
1.01
Marktkapitalisierung:
$14.65B
Einnahmen:
$220.00K
Nettoeinkommen (Verlust:
$-746.08M
KGV:
-19.54
EPS:
-1.0074
Netto-Cashflow:
$-211.81M
1W Leistung:
+12.33%
1M Leistung:
+15.63%
6M Leistung:
-20.45%
1J Leistung:
+4.57%
1-Tages-Spanne:
$18.98
$20.20
1-Wochen-Bereich:
$17.29
$20.20
52-Wochen-Spanne:
$15.55
$36.91
Summit Therapeutics Inc Stock (SMMT) Company Profile
Firmenname
Summit Therapeutics Inc
Sektor
Branche
Telefon
305-203-2034
Adresse
601 BRICKELL KEY DRIVE, MIAMI
Vergleichen Sie SMMT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
19.68 | 14.02B | 220.00K | -746.08M | -211.81M | -1.0074 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-17 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-09-17 | Eingeleitet | Barclays | Underweight |
| 2025-09-04 | Eingeleitet | Guggenheim | Buy |
| 2025-08-19 | Eingeleitet | Piper Sandler | Neutral |
| 2025-07-01 | Eingeleitet | UBS | Buy |
| 2025-06-11 | Eingeleitet | Leerink Partners | Underperform |
| 2025-03-26 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-03-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-03-12 | Eingeleitet | Evercore ISI | Outperform |
| 2025-02-28 | Eingeleitet | Goldman | Buy |
| 2025-01-08 | Eingeleitet | Truist | Buy |
| 2024-12-11 | Eingeleitet | Wells Fargo | Overweight |
| 2024-12-06 | Eingeleitet | Jefferies | Buy |
| 2024-11-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-09-27 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-08-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-05-07 | Eingeleitet | Citigroup | Buy |
| 2024-03-26 | Eingeleitet | Stifel | Buy |
| 2018-06-28 | Herabstufung | Janney | Buy → Neutral |
| 2018-05-02 | Eingeleitet | Janney | Buy |
| 2018-04-12 | Bestätigt | Needham | Buy |
| 2018-02-13 | Eingeleitet | BTIG Research | Buy |
| 2018-01-04 | Eingeleitet | SunTrust | Buy |
| 2017-12-01 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-11-16 | Bestätigt | RBC Capital Mkts | Outperform |
| 2016-10-05 | Bestätigt | Needham | Buy |
| 2016-09-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-03-30 | Eingeleitet | Needham | Buy |
| 2015-03-30 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Summit Therapeutics Inc Aktie (SMMT) Neueste Nachrichten
Cantor Fitzgerald reaffirms overweight rating on Summit Therapeutics (SMMT) before key 2026 catalyst - MSN
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Summit Therapeutics gives 17 new hires options on 214,331 shares - Stock Titan
How Summit Therapeutics Inc. stock valuations compare to rivalsJuly 2025 Technicals & Free Community Supported Trade Ideas - ulpravda.ru
Can Summit Therapeutics Inc. stock continue upward trendPrice Action Trading & Accelerated Earnings Growth - ulpravda.ru
A Look At Summit Therapeutics (SMMT) Valuation After Recent Share Price Strength - Yahoo Finance
Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinib - The Motley Fool
Summit Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - BioSpace
Price-Driven Insight from (SMMT) for Rule-Based Strategy - Stock Traders Daily
Cantor Fitzgerald Reaffirms Overweight Rating on Summit Therapeutics (SMMT) Before Key 2026 Catalyst - Finviz
Summit Therapeutics Earnings Notes - Trefis
15 Best Stocks Under $25 to Buy Now - Insider Monkey
Farther Finance Advisors LLC Makes New $1.14 Million Investment in Summit Therapeutics PLC $SMMT - MarketBeat
Capricorn Fund Managers Ltd Takes $10.25 Million Position in Summit Therapeutics PLC $SMMT - MarketBeat
Closing the Year With Gratitude and Shared Purpose – Summit Therapeutics - Oncodaily
Summit Therapeutics Inc. (SMMT) Stock Analysis: An 83.78% Potential Upside In Biotech - DirectorsTalk Interviews
Summit Therapeutics Shares Slip Following Mixed Results from Lung Cancer Trial - MSN
Summit Therapeutics PLC (NASDAQ:SMMT) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Is Summit Therapeutics Inc. stock a defensive play in 20252025 Price Momentum & Free Community Consensus Stock Picks - Улправда
How Summit Therapeutics Inc. stock compares to industry benchmarks2025 Big Picture & Long Hold Capital Preservation Plans - ulpravda.ru
Will Summit Therapeutics Inc. stock outperform Dow Jones indexPortfolio Return Report & AI Powered Buy and Sell Recommendations - ulpravda.ru
Summit Therapeutics stock rating reiterated by Cantor Fitzgerald - Investing.com Canada
Gap Down: How Summit Therapeutics Inc. stock valuations compare to rivalsWeekly Market Summary & Low Risk Profit Maximizing Plans - DonanımHaber
Gains Recap: Will Summit Therapeutics Inc. stock outperform Dow Jones indexJuly 2025 WrapUp & Weekly Stock Breakout Alerts - Улправда
Barclays Upgrades Summit Therapeutics (SMMT) - Nasdaq
Barclays Upgrades SMMT, Raises Price Target to $18 | SMMT Stock News - GuruFocus
Summit Therapeutics (NASDAQ:SMMT) Upgraded by Barclays to Equal Weight Rating - MarketBeat
Summit Therapeutics stock rating upgraded by Barclays on BLA timeline - Investing.com UK
Summit Therapeutics (NASDAQ:SMMT) Stock Price Crosses Below 50 Day Moving AverageHere's Why - MarketBeat
Trading Systems Reacting to (SMMT) Volatility - news.stocktradersdaily.com
Citi Asserts Buy Rating on Summit Therapeutics Inc. (SMMT) on Pipeline Development - Yahoo Finance
Citi asserts buy rating on Summit Therapeutics Inc. (SMMT) on pipeline development - MSN
Has Summit Therapeutics Rally Left Enough Upside After 448.6% Surge and DCF Upswing? - Yahoo Finance
2 Stocks Up Over 600% in the Past 3 Years With More Room to Run - Finviz
U.S. Markets Ended Tuesday Mixed As Galaxy Digital Led, Summit Therapeutics Lagged - Barron's
Summit Therapeutics (SMMT) Stock on December 9, 2025: Trial Optimism Collides With High Risk, High Volatility - ts2.tech
Summit Therapeutics (NASDAQ:SMMT) Shares Down 4.4%Here's Why - MarketBeat
Norges Bank Invests $29.58 Million in Summit Therapeutics PLC $SMMT - MarketBeat
New York State Common Retirement Fund Buys 227,513 Shares of Summit Therapeutics PLC $SMMT - MarketBeat
Schroder Investment Management Group Sells 89,090 Shares of Summit Therapeutics PLC $SMMT - MarketBeat
State Board of Administration of Florida Retirement System Boosts Stake in Summit Therapeutics PLC $SMMT - MarketBeat
Trading Near Its 52-Week Low, Is Summit Therapeutics a Good Stock to Buy Right Now? - Finviz
Why analysts upgrade Summit Therapeutics Inc. stockJuly 2025 Earnings & Weekly Chart Analysis and Guides - Newser
Summit Therapeutics Inc. (SMMT) Options Chain - Yahoo! Finance Canada
1 Reason I'll Never Sell Vertex Pharmaceuticals Stock - AOL.com
Finanzdaten der Summit Therapeutics Inc-Aktie (SMMT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Summit Therapeutics Inc-Aktie (SMMT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Oct 21 '25 |
Buy |
18.74 |
26,680 |
499,983 |
76,680 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Oct 21 '25 |
Buy |
18.74 |
26,680 |
499,983 |
76,680 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Sep 10 '25 |
Buy |
17.68 |
333,394 |
5,894,406 |
556,088,090 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Sep 11 '25 |
Buy |
18.07 |
5,000 |
90,350 |
556,093,090 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Sep 10 '25 |
Buy |
17.68 |
333,394 |
5,894,406 |
556,088,090 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Sep 11 '25 |
Buy |
18.07 |
5,000 |
90,350 |
556,093,090 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
May 30 '25 |
Option Exercise |
2.64 |
74,545 |
196,799 |
555,754,696 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
May 30 '25 |
Option Exercise |
2.64 |
74,545 |
196,799 |
555,754,696 |
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):